Promote Scientific Collaboration
Access to Unique Applications and Tools
HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website is currently a joint development effort by CHDI and UCLA, through the laboratory of Dr. Giovanni Coppola. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Latest news and publications from around the HD Ecosystem
- New molecule can reverse the Huntington's disease mutation in lab models
- Huntington’s disease therapeutics conference 2020 - Day 3
- Huntington’s disease therapeutics conference 2020 - Day 2
- Huntington’s disease therapeutics conference 2020 - Day 1
- Screening the entire genome for new drug targets for HD
- Harmine Acts as an Indirect Inhibitor of Intracellular Protein Aggregation.
- Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice.
- A role for PGC-1α in transcription and excitability of neocortical and hippocampal excitatory neurons.
- Correction to: Gait variability as digital biomarker of disease severity in Huntington's disease.
- Mutant Huntingtin affects toll-like receptor 4 intracellular trafficking and cytokine production in mast cells.
- Milton Keynes company appeals for temporary workers to cover staff on precautionary self-isolation
- Latest Research Report of Global Antibodies Market 2019-2027:Top Key Plyers like Roche ...
- Head-To-Head Analysis: Krystal Biotech (NASDAQ:KRYS) vs. Spark Therapeutics (NASDAQ:ONCE)
- Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study in Systemic Sclerosis
- NeuBase Therapeutics (NBSE) Gets a Buy Rating from Oppenheimer